Mount Sinai Scientists Discover Early Signs of Frontotemporal Dementia in Personalized Cerebral Organoids | Mount Sinai mountsinai.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mountsinai.org Daily Mail and Mail on Sunday newspapers.
UCLA Health
Dr. Gerald Levey at the entrance to Ronald Reagan UCLA Medical Center, in front of a wall honoring his service as vice chancellor of health sciences and dean of the David Geffen School of Medicine at UCLA. Elaine Schmidt |
June 29, 2021
Dr. Gerald Levey, who led the transformation of UCLA’s hospitals and medical school into a world-class academic health system, died at home of Parkinson’s disease on June 25. He was 84.
Levey served the campus as vice chancellor of medical sciences and dean of the David Geffen School of Medicine at UCLA from 1994 to 2010. During his tenure, Levey amassed an extraordinarily long list of achievements, crowned by the construction of the Ronald Reagan UCLA Medical Center and the sealing of a $200 million gift to the UCLA School of Medicine by entertainment executive David Geffen.
New immune players involved in metabolic liver disease eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.
Share
Multiple myeloma (a type of blood cancer) patients live much longer today than in the past, thanks to new targeted anti-myeloma drugs, but ultimately most develop resistance to the medications, and in some the disease is resistant to therapy from the start. Weizmann Institute of Science researchers, in collaboration with physicians from
Tel Aviv Sourasky Medical Center (TASMC), have made use of extremely sensitive genomic technology to reveal genetic pathways that characterize some of the more resistant cases of multiple myeloma.
Nature Medicine, may lead to a more informed, personalized treatment for these patients, and it paves the way to using this new technology for discovering additional disease targets in other cancers.